XORTX Therapeutics Inc. XRTX
Annual
Quarterly
No annual revenue total was found in XORTX Therapeutics Inc.'s SEC filings.
XORTX Therapeutics Inc. (XRTX) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
12.99M
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- XRTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Vancouver, British Columbia, Canada
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1729214
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 8, 2026 | Oct 8, 2026 |
| 6-K | Current report (foreign issuer) | Sep 18, 2026 | Sep 18, 2026 |
| 6-K | Current report (foreign issuer) | Sep 10, 2026 | Sep 10, 2026 |
| 6-K | Current report (foreign issuer) | Sep 9, 2026 | Sep 9, 2026 |
| 6-K | Current report (foreign issuer) | Sep 4, 2026 | Sep 4, 2026 |
| 6-K | Current report (foreign issuer) | Aug 28, 2026 | Aug 28, 2026 |
All 291 XORTX Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.